Speakers 2015
-
How to optimize current therapy of G1 patients (chairman)
-
Future therapeutic strategies with direct acting antivirals (chairman)
Presentation
-
ALAHDAB Yesim
Turkey
-
-
W2
Presentation
-
ARROYO Vicente
Spain
-
Acute-on-chronic liver failure is a new clinical entity
Presentation
-
-
State of the art lecture (chairman)
-
INF-free therapy in naïve patients
-
Take home messages
-
State of the art lecture (chairman)
-
How to optimize treatment in G4 patients? (chairman)
-
Take home message
Presentation
-
-
Staging of fibrosis: liver biopsy or indirect markers? (chairman)
-
Cirrhosis reversibility: who and why?
Presentation
-
-
Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking lunch workshop) (chairman)
Presentation
-
BENHAMOU Yves
France
-
Yes
-
Future therapeutic strategies with direct acting antivirals (chairman)
Presentation
-
-
Shortened therapy with IFN-based therapy
Presentation
-
-
Genotype 2, what’s new?
Presentation
-
BOYER Nathalie
France
-
Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking lunch workshop) (chairman)
Presentation
-
-
Traitements des patients rechuteurs et non répondeurs (French speaking lunch workshop) (chairman)
Presentation
-
-
Patients with comorbidities
Presentation
-
-
Special populations (chairman)
Presentation
-
-
Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking lunch workshop) (chairman)
Presentation
-
CALVARUSO Vincenza
Italy
-
Quantification of fibrosis and cirrhosis outcomes
Presentation
-
-
The control of HBV related liver disease (chairman)
Presentation
-
-
Can we predict HCC in chronic viral hepatitis?
-
How to improve access to therapy? (chairman)
-
Management of hepatocellular carcinoma in 2015
Presentation
-
-
Treatment of hepatitis C today and tomorrow
-
How to optimize treatment in G1 naive patients? (chairman)
Presentation
-
-
-
Staging of fibrosis: liver biopsy or indirect markers? (chairman)
Presentation
-
-
Comment optimiser le traitement des malades naïfs ? (French speaking lunch workshop) (chairman)
Presentation
-
-
Comment optimiser le traitement des malades naïfs ? (French speaking lunch workshop) (chairman)
Presentation
-
DI BISCEGLIE Adrian
USA
-
End-stage liver disease is a multifaceted condition (chairman)
Presentation
-
-
Special populations (chairman)
Presentation
-
DUSHEIKO Geoffrey
UK
-
Antiviral treatment in HCV cirrhotic patients on waiting list
-
Hepatitis C: new challenges in the era of DAAs (chairman)
Presentation
-
-
-
How to optimize treatment in G4 patients? (chairman)
Presentation
-
-
-
First line therapy of hepatitis B: interferon or analogues? (chairman)
Presentation
-
ESTRABAUD Emilie
France
-
HCV eradication with DAAs? (chairman)
Presentation
-
-
How to manage relapsers and non-responders to PEG IFN + RBV therapy (chairman)
Presentation
-
-
HBV and the immune response
Presentation
-
FLISIAK Robert
Poland
-
Access to treatment and disease burden
-
Presentation
-
-
Why genotype 3 is difficult to cure?
Presentation
-
-
How to improve access to therapy? (chairman)
-
HCV eradication with DAAs? (chairman)
Presentation
-
-
Optimal therapy of chronic hepatitis B (chairman)
Presentation
-
GOVAERE Olivier
Belgium
-
Hepatic progenitor cells in chronic liver diseases
Presentation
-
-
Clinical applications of HBsAg quantification (chairman)
Presentation
-
-
Traitements des patients rechuteurs et non répondeurs (French speaking lunch workshop) (chairman)
Presentation
-
HORBAN Andrzej
Poland
-
How to manage relapsers and non-responders to PEG IFN + RBV therapy (chairman)
Presentation
-
-
Workshop 1: Non invasive methods for fibrosis in the management of cirrhosis (chairman)
-
Presentation
-
-
New therapeutic strategies (chairman)
Presentation
-
JALAN Rajiv
UK
-
Treatment of HCV cirrhosis and transplanted patients (chairman)
Presentation
-
-
PEG IFN based therapy with 2nd wave DAAs
-
Triple therapy with telaprevir or boceprevir: management of side effects (chairman)
Presentation
-
-
Optimal therapy of chronic hepatitis B (chairman)
Presentation
-
-
The long term impact of treatment on the outcome of liver disease (chairman)
-
What have we learned from HBV clinical cohorts?
Presentation
-
KARAGINANNAKIS Dimitrios
Greece
-
Cardiomyopathy in cirrhosis
Presentation
-
KILANI Badreddine
Tunisia
-
Traitements des patients rechuteurs et non répondeurs (French speaking lunch workshop) (chairman)
Presentation
-
KOUCHNER Bernard
France
-
Hepatitis C: A public health priority
Presentation
-
-
How do I treat my HBeAg-negative patients?
Presentation
-
LARSSON Simon
Sweden
-
Workshop 3: The role of Pegylated IFN in HBV therapy (chairman)
-
W3
Presentation
-
LEQUOY Marie
France
-
Somatostatin receptors and HCC
Presentation
-
LEROY Vincent
France
-
Traitements des patients rechuteurs et non répondeurs (French speaking lunch workshop) (chairman)
Presentation
-
-
Short presentations (chairman)
-
HCV eradication with DAAs? (chairman)
Presentation
-
-
How to optimize current therapy of non G1 patients (chairman)
Presentation
-
LOANNIDOU Panagiota
Greece
-
-
W4
Presentation
-
MANNS Michael
Germany
-
-
New therapeutic strategies (chairman)
Presentation
-
-
Introduction
-
Restitution of workshops (chairman)
-
Awards and Conclusion
-
Introduction: Treatment of hepatitis C: towards the eradication?
-
How to improve access to therapy? (chairman)
-
Conclusion
-
Introduction: is HBV controlled?
-
State of the art lecture and Award (chairman)
-
Conclusion
Presentation
-
-
Clinical applications of HBsAg quantification (chairman)
-
HBsAg quantification to manage patients
Presentation
-
MATHURIN Philippe
France
-
Comment optimiser le traitement des malades naïfs ? (French speaking lunch workshop) (chairman)
Presentation
-
MEHTA Gautam
UK
-
-
W2
Presentation
-
MINDRUT Eugenia
Romania
-
-
W4
Presentation
-
-
End-stage liver disease is a multifaceted condition (chairman)
Presentation
-
MORENO Christophe
Belgium
-
Controversies in the management of cirrhosis (chairman)
-
Workshop 2: Management of acute alcoholic hepatitis (chairman)
Presentation
-
MOROZOV Sergey
Russia
-
Workshop 3: The role of Pegylated IFN in HBV therapy (chairman)
-
W3
Presentation
-
-
Short presentations (chairman)
Presentation
-
-
INF-free therapy in experienced patients
Presentation
-
-
Interferon ou analogue ? (French speaking lunch workshop) (chairman)
Presentation
-
PAIS Raluca
France
-
How to optimize treatment in G1 naive patients? (chairman)
Presentation
-
-
How do I treat my HBeAg-positive patients?
Presentation
-
Presentation
-
PARFIENUIK-KOWERDA Anna
Poland
-
Apoptosis in chronic hepatitis C
Presentation
-
-
Triple therapy with telaprevir or boceprevir: management of side effects (chairman)
Presentation
-
PERALVAREZ Manuel Rodriguez
Spain
-
-
W1
Presentation
-
PETERSEN Jorg
Germany
-
HBV: perspectives for treatment
Presentation
-
-
Workshop 4: Severe liver diseases in HIV patients (chairman)
-
Hepatitis C: new challenges in the era of DAAs (chairman)
-
How to optimize current therapy of G1 patients (chairman)
Presentation
-
-
Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking lunch workshop) (chairman)
Presentation
-
PUNETE SANCHEZ Ángela
Spain
-
Beta blockers in cirrhosis
Presentation
-
RADASAN Andreea
Romania
-
-
W1
Presentation
-
RATZIU Vlad
France
-
How to optimize treatment in G1 naive patients? (chairman)
Presentation
-
ROCKSTROH Juergen
Germany
-
HIV-HCV coinfections (chairman)
-
HIV co-infected patients
Presentation
-
-
Controversies in the management of cirrhosis (chairman)
-
Workshop 1: Non invasive methods for fibrosis in the management of cirrhosis (chairman)
-
Treatment of HCV cirrhosis and transplanted patients (chairman)
-
DAAs and transplant patients
Presentation
-
-
Controversy: Cure of HCV-related liver disease? (chairman)
-
Viral hepatitis: the past and the future
Presentation
-
SERFATY Lawrence
France
-
Workshop 2: Management of acute alcoholic hepatitis (chairman)
-
Patients monitoring after SVR
-
Awards and Conclusion
-
Predictors of response to IFN-based therapy
Presentation
-
-
No
Presentation
-
SOGNI Philippe
France
-
Clinical applications of HBsAg quantification (chairman)
Presentation
-
STREINU-CERCEL Anca
Romania
-
How to optimize treatment in G1 naive patients? (chairman)
Presentation
-
-
HIV-HCV coinfections (chairman)
Presentation
-
TOMASIEWICZ Krzysztof
Poland
-
Antiviral treatment in HCV cirrhotic patients on waiting list
Presentation
-
TOZUN Nurdan
Turkey
-
Workshop 4: Severe liver diseases in HIV patients (chairman)
-
The long term impact of treatment on the outcome of liver disease (chairman)
Presentation
-
-
Interferon ou analogue ? (French speaking lunch workshop) (chairman)
Presentation
-
TREPO Eric
France
-
Beta blockers in cirrhosis
Presentation
-
URBANEK Petr
Czech Republic
-
Triple therapy with telaprevir or boceprevir: management of side effects (chairman)
Presentation
-
VALLA Dominique
France
-
Treatment of HCV cirrhosis and transplanted patients (chairman)
-
The coagulation system in end-stage liver disease
Presentation
-
-
Restitution of workshops (chairman)
-
Comment optimiser le traitement des malades naïfs ? (French speaking lunch workshop) (chairman)
Presentation
-
-
Genotype 4, finally cured?
Presentation
-
WEILAND Ola
Sweden
-
Resistance
Presentation
-
YURDAYDIN Cihan
Turkey
-
First line therapy of hepatitis B: interferon or analogues? (chairman)
Presentation
-
-
Interferon ou analogue ? (French speaking lunch workshop) (chairman)
Presentation
-
ZEUZEM Stefan
Germany
-
How to optimize current therapy of non G1 patients (chairman)
Presentation
-
-
How to manage relapsers and non-responders to PEG IFN + RBV therapy (chairman)
Presentation
-
ZOULIM Fabien
France
-
The control of HBV related liver disease (chairman)
Presentation
-
